Safety and efficacy of thermal ablation for subpleural lung cancers
BackgroundThe study was conducted to assess the safety and efficacy of thermal ablation for the treatment of subpleural lung cancer.MethodsEighty ‐nine patients with 101 subpleural lung cancers were identified between January 2012 and July 2018 in our database and included in this study. Tumors were classified as adhering to cervical, costal, diaphragmatic, and mediastinal pleurae. Lesions were categorized based on their relationship to the pleura: close to the pleura, causing pleural indentation, and involving the pleura. The complete ablation rate, local progression‐free survival, complications, and associated factor...
Source: Thoracic Cancer - April 25, 2019 Category: Cancer & Oncology Authors: Fei Cao, Lin Xie, Han Qi, Shuanggang Chen, Lujun Shen, Ze Song, Weijun Fan Tags: ORIGINAL ARTICLE Source Type: research

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR ‐1210), a novel anti‐PD‐1 antibody
BackgroundA small proportion of patients with advanced esophageal squamous cell carcinoma (ESCC) could benefit from immune checkpoint inhibitors; however, reliable peripheral blood biomarkers for outcomes of anti ‐PD‐1 immunotherapy in ESCC have not been identified.MethodsThe data of 43 patients in the ESCC cohort of a phase I trial at our center were retrospectively reviewed. All patients were administered intravenous camrelizumab (SHR ‐1210), a novel anti‐PD‐1 antibody, at doses of 60 mg, 200 mg, or 400 mg (4‐week interval after first dose followed by a 2‐week schedule) until disease progression or intolera...
Source: Thoracic Cancer - April 24, 2019 Category: Cancer & Oncology Authors: Xi Wang, Bo Zhang, Xuelian Chen, Hongnan Mo, Dawei Wu, Bo Lan, Qun Li, Binghe Xu, Jing Huang Tags: ORIGINAL ARTICLE Source Type: research

Investigation of the effect of P14 promoter aberrant methylation on the biological function of human lung cancer cells
This study was conducted to investigate the effect of P14 promoter aberrant methylation on the biological function of human lung adenocarcinoma cells.MethodsWe used nested methylation ‐specific PCR (NMSP) to detect the methylation status of the p14ARF promoter region in SPCA1 and BEAS2B cell lines. The experimental groups were treated with 5‐aza‐2′‐deoxycytidine (5‐Aza). Quantitative real‐time PCR, Western blot, flow cytometry, and Cell Counting Kit 8 were used to d etect the expression of p14ARF messenger RNA and protein in each group, apoptosis, and cell proliferation inhibition, respectively.ResultsNMS...
Source: Thoracic Cancer - April 24, 2019 Category: Cancer & Oncology Authors: Bing ‐Yang Jia, Rong‐Hua Yang, Wen‐Jie Jiao, Kai‐Hua Tian Tags: ORIGINAL ARTICLE Source Type: research

Localized RNA interference therapy to eliminate residual lung cancer after incomplete microwave ablation
ConclusionPEG ‐PEI‐EGFR‐siRNA nanocomposites may be a supplemental therapy strategy to treat residual lung cancer after incomplete MWA. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 24, 2019 Category: Cancer & Oncology Authors: Fei Cao, Chao Wan, Lin Xie, Han Qi, Lujun Shen, Shuanggang Chen, Ze Song, Weijun Fan Tags: ORIGINAL ARTICLE Source Type: research

Molecular characterization of clinical responses to PD ‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients
This study is registered in th e Chinese Clinical Trial Registry (ChiCTR1900021395). (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 23, 2019 Category: Cancer & Oncology Authors: Peng Song, Xiaoxia Cui, Li Bai, Xiangdong Zhou, Xiaoli Zhu, Jian Zhang, Faguang Jin, Jianping Zhao, Chengzhi Zhou, Yanbin Zhou, Xiaoju Zhang, Kai Wang, Qi Wang, Yao Yu, Xiaoyu Zhang, Chunxue Bai, Li Zhang Tags: STUDY PROTOCOL Source Type: research

Clinical analysis of EGFR ‐positive non‐small cell lung cancer patients treated with first‐line afatinib: A Nagano Lung Cancer Research Group
BackgroundIn the LUX ‐Lung 3 and LUX‐Lung 6 trials, afatinib improved overall survival in previously untreated patients withEGFR 19del mutated non ‐small cell lung cancer (NSCLC) compared to chemotherapy. The appropriate management of adverse events and dose reduction of afatinib are important forEGFR ‐positive NSCLC patients. We conducted a retrospective and observational study of patients treated with first ‐line afatinib forEGFR ‐positive NSCLC in Nagano prefecture, Japan, focusing on efficacy and toxicities.MethodsWe retrospectively collected the medical records of NSCLC patients initially treated with afat...
Source: Thoracic Cancer - April 20, 2019 Category: Cancer & Oncology Authors: Kei Sonehara, Takashi Kobayashi, Kazunari Tateishi, Nobutoshi Morozumi, Fumiaki Yoshiike, Tsutomu Hachiya, Yasushi Ono, Keiichirou Takasuna, Toshihiko Agatsuma, Takeshi Masubuchi, Akemi Matsuo, Hozumi Tanaka, Akio Morikawa, Masayuki Hanaoka, Tags: ORIGINAL ARTICLE Source Type: research

Clinical features and outcomes of ALK rearranged non ‐small cell lung cancer with primary resistance to crizotinib
ConclusionPatients with primary resistance to crizotinib displayed unfavorable survival outcomes and the underlying mechanism cannot be identified in clinical features. Nevertheless, next ‐generation ALK inhibitors and chemotherapy after crizotinib progression could confer a therapeutic and survival benefit in this population. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 16, 2019 Category: Cancer & Oncology Authors: Di Ma, Yan Zhang, Puyuan Xing, Xuezhi Hao, Mengzhao Wang, Yan Wang, Li Shan, Tao Xin, Hongge Liang, Yang Du, Zhaohui Zhang, Li Liang, Junling Li Tags: ORIGINAL ARTICLE Source Type: research

Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma
ConclusionOur prediction model integrating genetic mutations, expression profiles, and clinicopathological features exhibited superior accuracy over the current tumor node metastasis staging system to prognosticate outcomes of patients with LUAD (overall survival 67% vs. 55%, recurrence ‐free survival 57% vs. 49%;P 
Source: Thoracic Cancer - April 16, 2019 Category: Cancer & Oncology Authors: Yueqiang Song, Donglai Chen, Xi Zhang, Yuping Luo, Siguang Li Tags: ORIGINAL ARTICLE Source Type: research

Early clear cell “sugar” lung cancer management: A case report and a brief literature review
This report highlights the importance of an adequate disease management team, including surgeons, oncologists, and pathologists, to identify the best therapeutic approach to improve survival rat es and the quality of life of patients affected by this rare disease. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 16, 2019 Category: Cancer & Oncology Authors: Marsela Sjniari, Evelina Miele, Valeria Stati, Claudio Di Cristofano, Daniele Diso, Ylenia Pecoraro, Federico Venuta, Silverio Tomao, Gian Paolo Spinelli Tags: CASE REPORT Source Type: research

Effect of histological subtype and treatment modalities on T1 –2 N0–1 small cell lung cancer: A population‐based study
BackgroundCombined small cell lung cancer (C ‐SCLC) is rare and its clinical features, appropriate treatment, and prognosis are poorly understood. Reports conflict over the prognosis of C‐SCLCs compared to pure small cell lung cancer.MethodsThe records of patients diagnosed with primary SCLC from 1988 to 2014 were extracted from the Surveillance, Epidemiology, and End Results database. The general features of C ‐SCLCs were compared to those of SCLCs. T1–2 N0–1 data was extracted and the effects of the histological subtype, treatment modality, and other prognostic factors on lung cancer‐specific survival...
Source: Thoracic Cancer - April 16, 2019 Category: Cancer & Oncology Authors: Seok ‐whan Moon, Jong‐hee Seo, Hyun‐woo Jeon, Mi Hyoung Moon Tags: ORIGINAL ARTICLE Source Type: research

Application of circulating tumor DNA for dynamic monitoring of advanced non ‐small cell lung cancer treatment response: An open‐label, multicenter, prospective, observational study protocol
Conclusions will be drawn from data collection and analysis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 13, 2019 Category: Cancer & Oncology Authors: Zhenlin Gao, Yanhong Shang, Xiaozhen Wang, Yuquan Ma, Fan Yang, Jun Wang, Kezhong Chen, Yan Zhang Tags: STUDY PROTOCOL Source Type: research

Feasibility and surgical outcomes of video ‐assisted thoracoscopic pulmonary resection in patients with advanced‐stage lung cancer after neoadjuvant chemoradiotherapy
ConclusionIn selected patients, VATS pulmonary resection after neoadjuvant CRT showed results comparable to that of thoracotomy in terms of postoperative outcomes, operative morbidities, and survival rate. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 13, 2019 Category: Cancer & Oncology Authors: Jee Won Suh, Seong Yong Park, Chang Young Lee, Jin Gu Lee, Dae Joon Kim, Hyo Chae Paik, Kyoung Young Chung Tags: ORIGINAL ARTICLE Source Type: research

Upregulation of phosphoserine phosphatase contributes to tumor progression and predicts poor prognosis in non ‐small cell lung cancer patients
ConclusionOur results indicate that PSPH may act as a putative oncogene in NSCLC, and may be a vital molecular marker for the metastasis and proliferation of NSCLC cells by regulating the AKT/AMPK signaling pathway. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 11, 2019 Category: Cancer & Oncology Authors: Li Liao, Huajian Yu, Mengxi Ge, Qiong Zhan, Ruofan Huang, Xiaoyu Ji, Xiaohua Liang, Xinli Zhou Tags: ORIGINAL ARTICLE Source Type: research

Successful treatment with nivolumab for SMARCA4 ‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report
We report the first case of SMARCA4‐deficient NSCLC with a high tumor mutation burden successfully treated with nivolumab. Anti‐PD‐1 antibodies might be a promising treatment strategy for patients with SMARCA4‐deficient NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 10, 2019 Category: Cancer & Oncology Authors: Tomoyuki Naito, Shigeki Umemura, Hiroshi Nakamura, Yoshitaka Zenke, Hibiki Udagawa, Keisuke Kirita, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Noriko Motoi, Keijyu Aokage, Masahiro Tsuboi, Genichiro Ishii, Koichi Goto Tags: CASE REPORT Source Type: research

Efficacy of PD ‐1/PD‐L1 inhibitors in patients with advanced non‐small cell lung cancer: A meta‐analysis of randomized clinical trials
BackgroundThis meta ‐analysis systematically evaluated the efficacy of PD‐1 and PD‐L1 inhibitors for the treatment of advanced non‐small cell lung cancer (NSCLC) and investigated the efficacy of first‐line therapy and PD‐1 versus PD‐L1 inhibitors.MethodsPubMed, The Cochrane Library, and Embase were searched up to November 2018 for randomized controlled trials (RCTs) for eligible studies. The outcome of interest was overall survival (OS). The methodology was based on the Preferred Reporting Items for Systematic Reviews and Meta ‐Analyses and Cochrane Collaboration guidelines. Data were pooled by using the ra...
Source: Thoracic Cancer - April 10, 2019 Category: Cancer & Oncology Authors: Tzu ‐Rong Peng, Ta‐Wei Wu Tags: ORIGINAL ARTICLE Source Type: research

Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune ‐related adverse effect: A case report
A 61 ‐year‐old woman with stage IVA lung adenocarcinoma exhibited high PD‐L1 expression. Pembrolizumab was administered as second‐line therapy. She developed destructive thyroiditis and her thyroid function started to decline during the administration of three to five courses. She was subsequentl y diagnosed with fulminant type 1 diabetes mellitus and ketoacidosis during the eighth course and insulin treatment was initiated. Pembrolizumab remained effective and was continued for 21 courses, even after the onset of diabetes mellitus. Immune‐checkpoint inhibitor treatment can be continued wi th hormone replacement ...
Source: Thoracic Cancer - April 9, 2019 Category: Cancer & Oncology Authors: Ryuya Edahiro, Mikako Ishijima, Hiroyuki Kurebe, Kohei Nishida, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Yukihiro Yano, Masahide Mori Tags: CASE REPORT Source Type: research

Benign disease prone to be misdiagnosed as malignant pulmonary nodules: Minute meningothelioid nodules
ConclusionsMPMNs tend to coexist with malignant tumors, mimicking the imaging findings of malignant pulmonary nodules, thus resulting in misdiagnosis. Dynamic monitoring or an invasive examination may help to distinguish MPMNs from malignant lesions. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 9, 2019 Category: Cancer & Oncology Authors: Xiao ‐Xiao Peng, Li‐Xu Yan, Chao Liu, Si‐Yun Wang, Wen‐Feng Li, Xing Gao, Xue‐Wu Wei, Qing Zhou Tags: ORIGINAL ARTICLE Source Type: research

Pulmonary sclerosing pneumocytoma presenting a peritumoral halo and an intervening lucent zone on computed tomography: Radiology –pathology correlation
Thoracic Cancer, EarlyView. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 9, 2019 Category: Cancer & Oncology Authors: Kyungsoo Bae, Dae Hyun Song, Kyung Nyeo Jeon, Sung Hwan Kim Tags: IMAGING IN THORACIC CANCER Source Type: research

P40 expression in small cell lung cancer: The presence of p40 ‐positive cells does not always indicate squamous differentiation
BackgroundSmall cell lung cancer (SCLC) is normally diagnosed with hematoxylin and eosin stains, although some cases require immunohistochemistry (IHC). P40 is highly sensitive and specific for squamous cell carcinoma and is thus considered the best marker for this cancer. However, the status of p40 expression in SCLC is not well known. The aim of this study was to analyze p40 expression in resected SCLC using IHC.MethodsForty ‐four surgically resected SCLC cases were enrolled. Clinical data were obtained from the patients’ medical records. Pathologists blinded to the patients’ clinical data reviewed the SCLC...
Source: Thoracic Cancer - April 7, 2019 Category: Cancer & Oncology Authors: Naoki Nakajima, Akihiko Yoshizawa, Koki Moriyoshi, Makoto Sonobe, Toshi Menju, Shinji Sumiyoshi, Hiroshi Date, Hironori Haga Tags: ORIGINAL ARTICLE Source Type: research

Radiotherapy for oligometastatic tumor improved the prognosis of patients with non ‐small cell lung cancer (NSCLC)
ConclusionOligometastatic non ‐progressive NSCLC patients may benefit from aggressive radiotherapy to the residual lesions with acceptable toxicity after systemic chemotherapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 7, 2019 Category: Cancer & Oncology Authors: Hong ‐yun Gong, Yi Wang, Guang Han, Qi‐bin Song Tags: ORIGINAL ARTICLE Source Type: research

Effect of lymph node examined count on accurate staging and survival of resected esophageal cancer
We examined the association between numbers of lymph nodes examined (LNEs) and accurate staging and survival to determine the optimal LNE count during esophagectomy using data from the Surveillance, Epidemiology, and End Results (SEER) cancer registry and the Department of Thoracic Surgery of a single institution (SI).MethodsA total of 7356 EC patients met our inclusion criteria from the SEER database and 1275 patients from SI. We applied multivariate models to investigate the relationship between the LNE count and LN metastasis and cancer ‐specific survival (CSS). Odds ratios (ORs) and hazard ratios (HRs) generated by t...
Source: Thoracic Cancer - April 7, 2019 Category: Cancer & Oncology Authors: Wenjie Xia, Suyao Liu, Qixing Mao, Bing Chen, Weidong Ma, Gaochao Dong, Lin Xu, Feng Jiang Tags: ORIGINAL ARTICLE Source Type: research

Nomogram to predict thymoma prognosis: A population ‐based study of 1312 cases
ConclusionSeveral prognostic factors for thymomas were identified. The nomogram developed in this study accurately predicted the 5 ‐year and 10‐year OS rates of patients with thymomas based on individual characteristics. Risk stratification using the survival nomogram could optimize individual therapy and follow‐up. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 7, 2019 Category: Cancer & Oncology Authors: Mengnan Zhao, Jiacheng Yin, Xiaodong Yang, Tian Jiang, Tao Lu, Yiwei Huang, Ming Li, Xinyu Yang, Miao Lin, Hao Niu, Cheng Zhan, Mingxiang Feng, Qun Wang Tags: ORIGINAL ARTICLE Source Type: research

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non ‐small cell lung cancer
BackgroundSingle agent immune checkpoint inhibitors (ICIs) improve survival outcomes compared to chemotherapy for advanced non ‐small cell lung cancer (NSCLC), but treatment efficacy widely varies. The combination of ICIs with chemotherapy has shown promising efficacy over chemotherapy alone; however, whether this strategy is superior to single agent ICIs for the treatment of advanced NSCLC remains unknown.MethodsThe records of 109 patients with advanced NSCLC who were administered at least one cycle of ICIs were retrospectively reviewed. Patients were grouped based on the presence or absence of a chemotherapy treatment ...
Source: Thoracic Cancer - April 5, 2019 Category: Cancer & Oncology Authors: Chih ‐Hsi Scott Kuo, Chin‐Chou Wang, Yu‐Chen Huang, Stelios Pavlidis, Chien‐Ying Liu, How‐Wen Ko, Fu‐Tsai Chung, Tin‐Yu Lin, Chih‐Liang Wang, Yi‐Ke Guo, Cheng‐Ta Yang Tags: ORIGINAL ARTICLE Source Type: research

Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database
ConclusionThis study has improved our understanding of resected MPM and shown that key factors, including age and histological type, are associated with overall survival. The nomogram is a reliable tool that can help clinicians turn individualized prediction into reality and maximize patient benefit by identifying the most beneficial treatment approach. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 5, 2019 Category: Cancer & Oncology Authors: Minglei Zhuo, Qiwen Zheng, Yujia Chi, Bo Jia, Jun Zhao, Meina WU, Tongtong AN, Yuyan Wang, Jianjie LI, Xinghui Zhao, Xue Yang, Jia Zhong, Hanxiao Chen, Zhi Dong, Jingjing Wang, Xiaoyu Zhai, Ziping Wang Tags: ORIGINAL ARTICLE Source Type: research

Synchronous primary glomus tumor in a patient with adenocarcinoma of the ipsilateral lung
We report a case of a primary glomus tumor occurring in the lung with adenocarcinoma in the ipsilateral lung as synchronous lung cancers in a 69 ‐year‐old man. He underwent lobectomy for adenocarcinoma and wedge resection for the glomus tumor with mediastinal lymph node dissection and was doing well without recurrence or metastasis at the last follow‐up. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 5, 2019 Category: Cancer & Oncology Authors: Ju Sik Yun, Sang Yun Song, Kook Joo Na, Seok Kim, Yoo Duk Choi Tags: CASE REPORT Source Type: research

Issue Information
Thoracic Cancer, Volume 10, Issue 4, Page 583-584, April 2019. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 4, 2019 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research

Comparative mitochondrial proteomic analysis of human large cell lung cancer cell lines with different metastasis potential
BackgroundLung cancer is a highly aggressive cancer with a poor prognosis and is associated with distant metastasis; however, there are no clinically recognized biomarkers for the early diagnosis and prediction of lung cancer metastasis. We sought to identify the differential mitochondrial protein profiles and understand the molecular mechanisms governing lung cancer metastasis.MethodsMitochondrial proteomic analysis was performed to screen and identify the differential mitochondrial protein profiles between human large cell lung cancer cell lines with high (L ‐9981) and low (NL‐9980) metastatic potential by two‐dime...
Source: Thoracic Cancer - April 4, 2019 Category: Cancer & Oncology Authors: Zhenkun Liu, Song Xu, Lu Li, Xiaorong Zhong, Chun Chen, Yaguang Fan, Wang Shen, Lingling Zu, Feng Xue, Min Wang, Qinghua Zhou Tags: ORIGINAL ARTICLE Source Type: research

Alteration in gene expression profiles of thymoma: Genetic differences and potential novel targets
ConclusionsOur results revealed gene expression differences between thymomas and thymic cysts, and identified key candidate genes/pathways that might be used as diagnostic markers and potential therapeutic targets to treat cancer metastasis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 1, 2019 Category: Cancer & Oncology Authors: Fan ‐Jie Meng, Shuo Wang, Jun Zhang, Yi‐Jie Yan, Chun‐Yang Wang, Chun‐Rui Yang, Zhi‐Yu Guan, Chang‐Li Wang Tags: ORIGINAL ARTICLE Source Type: research

Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: A case report and literature review
We report a case of an extracranial abscopal effect in a 71 ‐year‐old male patient with lung adenocarcinoma treated with atezolizumab and later combined with brain radiation for brain metastasis. The subsequent abscopal effect first manifested as pseudoprogression of the primary lesion in the lung before remission was confirmed. This case suggests that i mmunotherapy increases the chance of an abscopal effect occurring after radiation therapy for brain metastases in patients with primary tumors with low immunogenicity. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 30, 2019 Category: Cancer & Oncology Authors: Xinqing Lin, Tingting Lu, Zhanhong Xie, Yinyin Qin, Ming Liu, Xiaohong Xie, Shiyue Li, Chengzhi Zhou Tags: CASE REPORT Source Type: research

What have we learned from Linxian esophageal cancer etiological studies?
Esophageal cancer is the sixth leading cause of cancer death in the world. Esophageal squamous cell carcinoma (ESCC) accounts for 90% of esophageal cancer cases, over half of which occur in China. Linxian, a county located in the North Central Taihang Mountain range, has the highest ESCC mortality rate, which may be the leading cause of death in this area. In a decades ‐long research program in Linxian, Chinese and international scientists have exerted great efforts to describe the epidemiological characteristics and elucidate the etiology of ESCC. A systematic review and summary of the current knowledge gained from prev...
Source: Thoracic Cancer - March 29, 2019 Category: Cancer & Oncology Authors: Shao ‐Ming Wang, Christian C. Abnet, You‐Lin Qiao Tags: MINI REVIEW Source Type: research

Favorable predictors for survival in advanced ALK ‐positive non‐small cell lung cancer patients beyond crizotinib resistance
ConclusionLong PFS with crizotinib ( ≥10.4 months), intracranial progression, and use of next‐generationALK inhibitors might be favorable predictors for OS in advancedALK‐positive NSCLC patients. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 28, 2019 Category: Cancer & Oncology Authors: Haiyan Xu, Guangjian Yang, Lu Yang, Yaning Yang, Di Ma, Junling Li, Xuezhi Hao, Puyuan Xing, Yan Wang Tags: ORIGINAL ARTICLE Source Type: research

Clinicopathological characteristics, diagnosis, and prognosis of pregnancy ‐associated breast cancer
ConclusionPABC is an aggressive form of breast cancer associated with advanced stage at diagnosis. Despite the existing difficulties in diagnosis, imaging examinations are indispensable. Early diagnosis and multidisciplinary therapy, including anti ‐HER2 targeted therapy, may be important to improve prognosis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 28, 2019 Category: Cancer & Oncology Authors: Bin Wang, Yanfang Yang, Zhansheng Jiang, Jing Zhao, Yiran Mao, Jun Liu, Jin Zhang Tags: ORIGINAL ARTICLE Source Type: research

Complete resection of primary pulmonary malignancy extending into the left atrium via the left pulmonary vein using cardiopulmonary bypass and single incision: A case series
We report two successful cases of safe and rapid complete resection of primary pulmonary malignancy extending into the left atrium with the support of CPB via median sternotomy. Our experiences support the application of CPB in extended left pulmonary resections to achieve complete resection. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 27, 2019 Category: Cancer & Oncology Authors: Young Woo Do, Youngok Lee, Gun ‐Jik Kim, Joon Yong Cho, Deok Heon Lee Tags: CASE REPORT Source Type: research

Efficacy of subsequent docetaxel +/ − ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
ConclusionSubsequent cytotoxic chemotherapy, especially immediately after nivolumab, has better treatment efficacy than that of regimens without ICI pretreatment. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 26, 2019 Category: Cancer & Oncology Authors: Nobumasa Tamura, Hidehito Horinouchi, Katsutoshi Sekine, Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe Tags: ORIGINAL ARTICLE Source Type: research

High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma
ConclusionsCollectively, our results demonstrate that KIFl8A is highly expressed in LUAD. KIFl8A plays an important role in LUAD cell proliferation, but is a poor prognostic factor. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 25, 2019 Category: Cancer & Oncology Authors: Xiaoqing Li, Meirong Liu, Zheng Zhang, Linlin Zhang, Xingmei Liang, Linlin Sun, Diansheng Zhong Tags: ORIGINAL ARTICLE Source Type: research

Updates to the antitumor mechanism of oncolytic virus
Oncolytic viruses (OVs) are promising new therapeutic agents in the field of malignant tumor treatment. OVs can achieve the goal of targeted therapy by selectively killing tumor cells and inducing specific antitumor immunity. The key roles of OVs are tumor targeting and tumor killing mechanisms. Recently, molecular biotechnology has been used to optimize the transformation of wild virus strains in order to ensure a stronger oncolytic effect and lower adverse reactions, to enable testing in clinical trials as an antitumor drug. The main purpose of this review is to provide a description of oncolytic mechanisms, clinical stu...
Source: Thoracic Cancer - March 22, 2019 Category: Cancer & Oncology Authors: Yang Bai, Peng Hui, Xiaoyu Du, Xing Su Tags: MINI REVIEW Source Type: research

First ‐line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non‐squamous non‐small cell lung cancer with wild‐type driver genes: A real‐world study in China
BackgroundThe study was conducted to compare the effectiveness and safety of pemetrexed/carboplatin or cisplatin/bevacizumab (PemPBev) and paclitaxel/carboplatin/bevacizumab (PacCBev) as first ‐line therapy for advanced non‐squamous non‐small cell lung cancer (NS‐NSCLC) patients with wild‐type driver genes in a real‐world setting.MethodsWe retrospectively collected the medical records of advanced NS ‐NSCLC patients with wild‐type driver genes administered first‐line PemPBev or PacCBev therapy at Shanghai Chest Hospital between January 2014 and June 2016, and analyzed the differences in survival outcomes, ...
Source: Thoracic Cancer - March 22, 2019 Category: Cancer & Oncology Authors: Qing Chang, Yanwei Zhang, Jianlin Xu, Runbo Zhong, Huiping Qiang, Bo Zhang, Baohui Han, Jialin Qian, Tianqing Chu Tags: ORIGINAL ARTICLE Source Type: research

18Fluorodeoxyglucose ‐positron emission tomography/computed tomography features of suspected solitary pulmonary lesions in breast cancer patients following previous curative treatment
ConclusionsCT border, FDG uptake, hilar and/or mediastinal lymph node metastasis, and pleural metastasis are potential markers for diagnosis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 21, 2019 Category: Cancer & Oncology Authors: Lei Zhu, Haiman Bian, Lieming Yang, Jianjing Liu, Wei Chen, Xiaofeng Li, Jian Wang, Xiuyu Song, Dong Dai, Zhaoxiang Ye, Wengui Xu, Xiaozhou Yu Tags: ORIGINAL ARTICLE Source Type: research

Knockdown of KLF5 promotes cisplatin ‐induced cell apoptosis via regulating DNA damage checkpoint proteins in non‐small cell lung cancer
ConclusionKLF5 plays a significant role in the DNA damage response by regulating DNA damage checkpoint proteins. Inhibition ofKLF5 may be a potential therapeutic target for NSCLC patients with cisplatin resistance. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 21, 2019 Category: Cancer & Oncology Authors: Hao Zhang, Fei Shao, Wei Guo, Yibo Gao, Jie He Tags: ORIGINAL ARTICLE Source Type: research

miR ‐194 suppresses high glucose‐induced non‐small cell lung cancer cell progression by targeting NFAT5
ConclusionOur findings provide new insight into the mechanism of NSCLC progression. Therapeutically, miR ‐194 may serve as a potential target for the treatment of lung cancer patients with DM. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 21, 2019 Category: Cancer & Oncology Authors: Xuying Meng, Zhenjin Li, Saijun Zhou, Shumin Xiao, Pei Yu Tags: ORIGINAL ARTICLE Source Type: research

Radiotherapy is an independent prognostic marker of favorable prognosis in non ‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
ConclusionPrevious RT was an independent prognostic marker of favorable prognosis after nivolumab administration and improved the response rate to nivolumab treatment. Previous RT was clinically identified to have a synergistic effect with nivolumab treatment, increasing the response rate and improving the outcome of patients with advanced NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 19, 2019 Category: Cancer & Oncology Authors: Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, Atsuto Mouri, Yu Miura, Ayako Shiono, Fuyumi Nishihara, Yoshitake Murayama, Shin ‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu Tags: ORIGINAL ARTICLE Source Type: research

Increased expression of TRPV1 in patients with acute or chronic cough after lung cancer surgery
BackgroundWe investigated preoperative and postoperative TRPV1, bradykinin (BK), and prostaglandin e ‐2 (PGE2) levels in patients who underwent lung cancer surgery and evaluated the correlations between these levels and the development of acute or chronic cough after surgery.MethodsWe evaluated 60 patients with non ‐small cell lung cancer who underwent lobectomy at our center between August and October 2018. TRPV1, BK, and PGE2 levels were determined by enzyme‐linked immunosorbent assay and postoperative cough was assessed using the visual analog scale (VAS).ResultsThe postoperative serum TRPV1, BK, and PEG2 levels o...
Source: Thoracic Cancer - March 18, 2019 Category: Cancer & Oncology Authors: Yong ‐fu Zhu, Sheng‐bing Wu, Mei‐qi Zhou, Ming‐ran Xie, Ran Xiong, Shi‐bin Xu, Guang‐wen Xu Tags: ORIGINAL ARTICLE Source Type: research

Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin ‐induced apoptosis
ConclusionThe combined regimen of the proteasome inhibitor delanzomib with Dox chemotherapy may become an effective strategy for breast cancer therapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 18, 2019 Category: Cancer & Oncology Authors: Mopei Wang, Li Liang, Jiaxiong Lu, Yang Yu, Yanling Zhao, Zhenfeng Shi, Hui Li, Xin Xu, Yuxian Yan, Yan Niu, Zhentao Liu, Lin Shen, Hong Zhang Tags: ORIGINAL ARTICLE Source Type: research

Fluorine ‐18‐fluorodeoxyglucose‐positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal‐related events
ConclusionOur findings suggest that FDG ‐PET evaluation in metastatic bone lesions could be useful to predict initial pain and subsequent clinical outcomes of local bone status in initially diagnosed lung cancer patients with bone metastasis. In addition, our results suggest that there could be histological differences in the biological activity of bone metastatic lesions in lung cancer, especially between SCLC and NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 18, 2019 Category: Cancer & Oncology Authors: Daisuke Gomi, Toshirou Fukushima, Takashi Kobayashi, Nodoka Sekiguchi, Tomonobu Koizumi, Kazuhiko Oguchi Tags: ORIGINAL ARTICLE Source Type: research

Comprehensive analysis of circular RNA profiling in AZD9291 ‐resistant non‐small cell lung cancer cell lines
ConclusionOur results reveal that circRNAs may play a role in NSCLC AZD9291 resistance and might be a promising molecular target candidate for gene therapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 18, 2019 Category: Cancer & Oncology Authors: Tianxiang Chen, Jizhuang Luo, Yu Gu, Jia Huang, Qingquan Luo, Yunhai Yang Tags: ORIGINAL ARTICLE Source Type: research

Re ‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
BackgroundRe ‐biopsy is important for exploring resistance mechanisms, especially for non‐small cell lung cancer (NSCLC) patients who develop resistance to EGFR‐tyrosine kinase inhibitors (TKIs). Liquid biopsy using circulating tumor DNA has come into use for this purpose. This retrospective study investig ated the status of re‐biopsy and liquid biopsy in NSCLC patients withEGFR mutations and evaluated their effect on clinical strategies and prognosis.MethodsFive hundred fifty ‐five NSCLC patients with resistance to EGFR‐TKIs were included and divided into three groups: re‐biopsy, liquid biopsy, and no re‐b...
Source: Thoracic Cancer - March 18, 2019 Category: Cancer & Oncology Authors: Juan Zhou, Chao Zhao, Jing Zhao, Qi Wang, Xiangling Chu, Jiayu Li, Fei Zhou, Shengxiang Ren, Xuefei Li, Chunxia Su, Caicun Zhou Tags: ORIGINAL ARTICLE Source Type: research

Association between tooth loss and upper gastrointestinal cancer: A 30 ‐year follow‐up of the Linxian Dysplasia Nutrition Intervention Trial Cohort
BackgroundThis prospective study investigated the association between tooth loss and upper gastrointestinal (UGI) cancer mortality in the Linxian Dysplasia Nutrition Intervention Trial Cohort.MethodsSubjects were categorized into three groups according to age at baseline. No missing teeth and less or greater than median tooth loss in each group was defined as none, moderate, and severe, respectively. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated using the Cox proportional hazard model.ResultsThrough 30 September 2015, 541 esophageal squamous cell carcinoma (ESCC), 284 gastric cardia carcinoma (G...
Source: Thoracic Cancer - March 18, 2019 Category: Cancer & Oncology Authors: Su Zhang, Pei Yu, Jian ‐Bing Wang, Jin‐Hu Fan, You‐Lin Qiao, Philip R. Taylor Tags: ORIGINAL ARTICLE Source Type: research

Analysis of factors related to chronic cough after lung cancer surgery
In this study, we investigated the relationship between chronic cough and clinicopathological features in postoperative patients with non ‐small cell lung cancer (NSCLC) and evaluated the effectiveness of acupuncture therapy for the treatment of postoperative chronic cough in patients with NSCLC.MethodsWe retrospectively evaluated 171 patients with NSCLC who received lobectomy at our center between September 2017 and February 2018. The Mandarin Chinese version of the Leicester Cough Questionnaire (LCQ ‐MC) was used to evaluate the degree of cough in patients. Postoperative cough was assessed by a visual analog scale (V...
Source: Thoracic Cancer - March 15, 2019 Category: Cancer & Oncology Authors: Ming ‐ran Xie, Yong‐fu Zhu, Mei‐qi Zhou, Sheng‐bing Wu, Guang‐wen Xu, Shi‐bin Xu, Mei‐qing Xu Tags: ORIGINAL ARTICLE Source Type: research

Trends in endpoint selection and result interpretation in advanced non ‐small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study
The objective of this review was to investigate trends in clinical trial design, specifically, the primary outcomes used, interpretation of results, and the magnitude of the benefits described in phase III controlled clinical trials in the first ‐line treatment of patients with advanced non‐small cell lung cancer (NSCLC).MethodsSeventy ‐six trials published between 2000 and 2012 were selected from a total of 122 identified in a structured search.ResultsOverall survival (OS) was evaluated as the primary study endpoint in 50 (65.8%) trials, followed by progression ‐free survival (PFS) in 15 (19.7%), and other variabl...
Source: Thoracic Cancer - March 13, 2019 Category: Cancer & Oncology Authors: Cristina Fern ández‐López, Miguel Ángel Calleja‐Hernández, Jaime Espín Balbino, José Cabeza‐Barrera, José Expósito‐Hernández Tags: ORIGINAL ARTICLE Source Type: research

Persistence of smoking induced non ‐small cell lung carcinogenesis by decreasing ERBB pathway‐related microRNA expression
ConclusionOur findings provide evidence to explain the mechanism of lung cancer development in smokers. (Source: Thoracic Cancer)
Source: Thoracic Cancer - March 13, 2019 Category: Cancer & Oncology Authors: Lianmin Zhang, Hailong Wang, Changli Wang Tags: ORIGINAL ARTICLE Source Type: research